Dendritic cells license regulatory B cells to produce IL-10 and mediate suppression of antigen-specific CD8 T cells

Boldison, Joanne; Rosa, Larissa Camargo da; Davies, Joanne; Li, Wen; Wong, F. Susan

doi:10.1038/s41423-019-0324-z

Cited by 61 publications

(53 citation statements)

References 43 publications

(58 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…121,122 Although B cells play crucial roles in humoral immunity by antibody production, they also contribute to cellular immunity by serving as APCs to enhance T-cell-mediated immunity and by modulating immune responses through cytokines or regulatory B cells. 123,124 Moreover, B cells help maintain secondary lymphoid organ architecture and facilitate the formation of tertiary lymphoid structures (TLSs), highly organized structures composed of aggregates of immune cells such as T cells, B cells, and follicular DCs, at sites of chronic inflammation and tumors. 125 TLSs are particularly important for the recruitment and local activation of B cells and T cells, and thus contribute to long-term immunity.…”

Section: Tumor-infiltrating Immune Cells and Their Associations With mentioning

confidence: 99%

The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications

2020

View full text Add to dashboard Cite

Immunotherapy has revolutionized cancer treatment and rejuvenated the field of tumor immunology. Several types of immunotherapy, including adoptive cell transfer (ACT) and immune checkpoint inhibitors (ICIs), have obtained durable clinical responses, but their efficacies vary, and only subsets of cancer patients can benefit from them. Immune infiltrates in the tumor microenvironment (TME) have been shown to play a key role in tumor development and will affect the clinical outcomes of cancer patients. Comprehensive profiling of tumor-infiltrating immune cells would shed light on the mechanisms of cancer-immune evasion, thus providing opportunities for the development of novel therapeutic strategies. However, the highly heterogeneous and dynamic nature of the TME impedes the precise dissection of intratumoral immune cells. With recent advances in single-cell technologies such as single-cell RNA sequencing (scRNA-seq) and mass cytometry, systematic interrogation of the TME is feasible and will provide insights into the functional diversities of tumor-infiltrating immune cells. In this review, we outline the recent progress in cancer immunotherapy, particularly by focusing on landmark studies and the recent single-cell characterization of tumor-associated immune cells, and we summarize the phenotypic diversities of intratumoral immune cells and their connections with cancer immunotherapy. We believe such a review could strengthen our understanding of the progress in cancer immunotherapy, facilitate the elucidation of immune cell modulation in tumor progression, and thus guide the development of novel immunotherapies for cancer treatment.

show abstract

Section: Tumor-infiltrating Immune Cells and Their Associations With mentioning

confidence: 99%

The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications

2020

View full text Add to dashboard Cite

show abstract

“…Mature mDCs can interact with CD4+ lymphocytes triggering an inflammatory activity of Th1 and Th17 subtypes, and enhancing activity of cytotoxic CD8+ lymphocytes. Additionally, some data suggest that mutual interactions between mDC and B lymphocytes might be responsible for induction of autoantibodies secretion [25][26].…”

Section: Discussionmentioning

confidence: 99%

Evaluating the Role of Circulating Dendritic Cells in Methimazole-Treated Pediatric Graves’ Disease Patients

Starosz¹,

Stożek²,

Moniuszko³

et al. 2020

Preprint

View full text Add to dashboard Cite

Graves’ disease (GD) is hyperthyroidism associated with organ-specific autoimmune inflammation. GD occurs more frequently in adults than in children, however, pediatric patients are a therapeutic challenge due to cycles of remissions and relapses requiring constant monitoring at every stage of treatment administered. Dendritic cells (DCs) are considered a link between innate and adaptive immunity. DCs as antigen-presenting cells (APCs) are involved in antigen presentation to T lymphocytes, thereby, initiate shift towards effector cells. In accordance, DCs participates also in the modulation of tolerance to specific antigens. To date, the data on DC role in Graves’ pathological processes are scarce. Therefore, here we evaluated frequencies and role of circulating DCs in GD pediatric patients treated with methimazole. Flow cytometric analysis was implemented to evaluate mDC1, mDC2 and pDC cells and their correlation with clinical GD-related parameters. We found significantly higher levels of DC subsets in patients at admission. Furthermore, methimazole treatment seemed to effectively reduce subsets of DCs which, in addition, were found to differentialy correlate with thyroid function. Our study shed a new light on DCs role in pediatric GD pathomechanism. Further studies are required for mechanistic assessment of DCs exact role in disease progression and influence on thyroid function.

show abstract

“…Also, Breg-derived IL-10 is important for promoting regulatory T cells (Tregs), which further contribute to immune suppression (24). Bregs via increased expression of TGF-β1 and IL-10 can induce anergy of CD8+ T cells and apoptosis of CD4+ T cells, respectively (25,26). With this in mind, it is apparent that Bregs act to dampen immune activity which may contribute to a less robust antitumor immune response.…”

Section: B Cells Subtypes and Functionsmentioning

confidence: 99%

Duality of B Cell-CXCL13 Axis in Tumor Immunology

2020

View full text Add to dashboard Cite

Tumor immunity is a rapidly evolving area of research consisting of many possible permutations of immune cell tumor interactions that are dependent upon cell type, tumor type, and stage in tumor progression. At the same time, the majority of cancer immunotherapies have been focused on modulating the T cell-mediated antitumor immune response and have largely ignored the potential utility that B cells possess with respect to tumor immunity. Therefore, this motivated an exploration into the role that B cells and their accompanying chemokine, CXCL13, play in tumor immunity across multiple tumor types. Both B cells and CXCL13 possess dualistic impacts on tumor progression and tumor immunity which is furthered detail in this review. Specifically, various B cells subtypes are able to suppress or enhance several important immunological functions. Paradoxically, CXCL13 has been shown to drive several pro-growth and invasive signaling pathways across multiple tumor types, while also, correlating with improved survival and immune cell tumor localization in other tumor types. Potential tools for better elucidating the mechanisms by which B cells and CXCL13 impact the antitumor immune response are also discussed. In addition, multiples strategies are proposed for modulating the B cell-CXCL13 axis for cancer immunotherapies.

show abstract

Dendritic cells license regulatory B cells to produce IL-10 and mediate suppression of antigen-specific CD8 T cells

Cited by 61 publications

References 43 publications

The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications

The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications

Evaluating the Role of Circulating Dendritic Cells in Methimazole-Treated Pediatric Graves’ Disease Patients

Duality of B Cell-CXCL13 Axis in Tumor Immunology

Contact Info

Product

Resources

About